Discussion on access to Cannabis-derived drugs in the light of Health Innovation in Brazil

• Autor(a) principal: Villas Bôas, Glauco de Kruse
• Data de Publicação: 2020
• Outros Autores: Rezende, Mayara de Azeredo
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Fitos
• Texto Completo: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/960
• topic: Innovation and Health; Access; Cannabis sp. drugs; Inovação e Saúde; Acesso; Medicamentos da Cannabis

The discussion on access to Cannabis-derived drugs, in the light of Health Innovation in Brazil, corresponds to a case study, constructed through narratives frames. The narrative of Health Innovation describes theoretical concepts of an evolutionary aspect of the economy and the elaboration of a National Health Innovation System from the perspective of the Health Industrial Economic Complex. The Research on the Medical Use of Cannabis reveals the contribution of science by opening the path to innovation. The history of Judicialization and Regulation as a means of access to medicines in Brazil, shows that judicial decisions can deter the public health policies implementation budget. It also registers the RDC 327, 2019 publication from Anvisa, providing rules for manufacturing and importing of Cannabis products in Brazil, without solving the access to these drugs. A discussion in a new perspective indicates that Productive Development Partnerships (PDPs) as an alternative to the national production of Cannabis drugs, expanding access to them. This study concludes that new regulatory measures are necessary, in addition to the recognition of Cannabis drugs as strategic for the Unified Health System.